Publications by authors named "Kaendi Munguti"

Malaria remains a public health priority in Rwanda. The use of insecticide-treated nets (ITNs) is a key malaria prevention tool. However, expanding pyrethroid resistance threatens the gains made in malaria control.

View Article and Find Full Text PDF

Intermittent preventive therapy during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended in areas of moderate to high malaria transmission intensity. As a result of the increasing prevalence of SP resistance markers, IPTp-SP was withdrawn from Rwanda in 2008. Nonetheless, more recent findings suggest that SP may improve birthweight even in the face of parasite resistance, through alternative mechanisms that are independent of antimalarial effects.

View Article and Find Full Text PDF

Background: Malaria during pregnancy can cause serious consequences including maternal anemia and low birthweight (LBW). Routine antenatal care (ANC) in Rwanda includes malaria symptom screening at each ANC visit. This cluster randomized controlled trial investigated whether adding intermittent screening with a malaria rapid diagnostic test at each routine ANC visit and treatment of positives during pregnancy (ISTp) is more effective than routine ANC for reducing malaria prevalence at delivery.

View Article and Find Full Text PDF

Background: Partial artemisinin resistance is suspected if delayed parasite clearance (ie, persistence of parasitaemia on day 3 after treatment initiation) is observed. Validated markers of artemisinin partial resistance in southeast Asia, Plasmodium falciparum kelch13 (Pfkelch13) R561H and P574L, have been reported in Rwanda but no association with parasite clearance has been observed. We aimed to establish the efficacy of artemether-lumefantrine and genetic characterisation of Pfkelch13 alleles and their association with treatment outcomes.

View Article and Find Full Text PDF
Article Synopsis
  • Artemisinin resistance, marked by delayed clearance of P. falciparum after treatment, has been prevalent in Southeast Asia but hasn't been observed in Africa until now.
  • A study in Rwanda identified the Pfkelch13 R561H mutation in 7.4% of patients, suggesting it may be linked to artemisinin resistance.
  • This finding indicates the emergence of this resistance mechanism in Africa, which could threaten the effectiveness of current antimalarial treatments.
View Article and Find Full Text PDF
Article Synopsis
  • The decline in child mortality in Rwanda from 1996-2010 was significantly linked to increased malaria control measures, including indoor residual spraying (IRS) and insecticide-treated net (ITN) distribution.
  • Child mortality dropped by 61% during this period, and severe anemia in young children decreased by 71% from 2005 to 2010, attributed to rising use of malaria prevention strategies.
  • Enhanced access to effective malaria treatment and increased healthcare-seeking behaviors among caregivers contributed to these improvements, indicating that malaria interventions were crucial to the overall decline in child mortality in Rwanda.
View Article and Find Full Text PDF

Background: Maternal mortality remains high in developing countries and data to monitor indicators of progress in maternal care is needed. We examined the status of maternal care before and after health care worker (HCW) training in WHO recommended Focused Antenatal Care.

Methods: An initial cross-sectional survey was conducted in 2002 in Asembo and Gem in western Kenya among a representative sample of women with a recent birth.

View Article and Find Full Text PDF

Background: In Nigeria ACT use at the community level has not been evaluated and the use of antimalarial drugs (commonly chloroquine (CQ)) at home has been shown to be largely incorrect. The treatment regimen of ACT is however more complicated than that of CQ. There is thus a need to determine the feasibility of using ACT at the home level and determine community perception on its use.

View Article and Find Full Text PDF

Background: The Home Management of Malaria (HMM) strategy was developed using chloroquine, a now obsolete drug, which has been replaced by artemisinin-based combination therapy (ACT) in health facility settings. Incorporation of ACT in HMM would greatly expand access to effective antimalarial therapy by the populations living in underserved areas in malaria endemic countries. The feasibility and acceptability of incorporating ACT in HMM needs to be evaluated.

View Article and Find Full Text PDF